Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordis
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
09:30am, Thursday, 06'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09:10am, Thursday, 06'th Mar 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 6, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NVO
The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
05:45am, Thursday, 06'th Mar 2025
NEW YORK , March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class peri
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
04:28am, Thursday, 06'th Mar 2025
Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
09:30pm, Wednesday, 05'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities la
SAN FRANCISCO, CA / ACCESS Newswire / March 5, 2025 / Novo Nordisk A/S (NYSE:NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
05:19pm, Wednesday, 05'th Mar 2025
Novo Nordisk's (NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance tha
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
05:00pm, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
04:30pm, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed a
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
02:51pm, Wednesday, 05'th Mar 2025
Novo Nordisk (NVO) is lowering the price of its popular weight-loss drug Wegovy for some patients paying out of pocket.
Novo Nordisk cuts Wegovy prices in half for cash-paying consumers
01:11pm, Wednesday, 05'th Mar 2025
Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy to reach more people who aren't covered.
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
10:56am, Wednesday, 05'th Mar 2025
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
10:30am, Wednesday, 05'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such investors
